Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INFU 
InfuSystems Holdings Inc (INFU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: INFU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.75
1 Year Target Price $13.75
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.73% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 206.30M USD | Price to earnings Ratio 42.08 | 1Y Target Price 13.75 |
Price to earnings Ratio 42.08 | 1Y Target Price 13.75 | ||
Volume (30-day avg) 4 | Beta 1.83 | 52 Weeks Range 4.61 - 11.04 | Updated Date 09/16/2025 |
52 Weeks Range 4.61 - 11.04 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.63% | Operating Margin (TTM) 10.49% |
Management Effectiveness
Return on Assets (TTM) 6.73% | Return on Equity (TTM) 9.39% |
Valuation
Trailing PE 42.08 | Forward PE 29.85 | Enterprise Value 236036236 | Price to Sales(TTM) 1.47 |
Enterprise Value 236036236 | Price to Sales(TTM) 1.47 | ||
Enterprise Value to Revenue 1.7 | Enterprise Value to EBITDA 10.09 | Shares Outstanding 20426000 | Shares Floating 18080042 |
Shares Outstanding 20426000 | Shares Floating 18080042 | ||
Percent Insiders 6.61 | Percent Institutions 75.26 |
Upturn AI SWOT
InfuSystems Holdings Inc
Company Overview
History and Background
InfuSystems Holdings Inc. was founded in 1992 and is headquartered in Rochester Hills, Michigan. It provides infusion therapy services and equipment to patients in their homes and at ambulatory infusion suites.
Core Business Areas
- Infusion Services: InfuSystems focuses on providing infusion therapy for various conditions, including autoimmune diseases, neurological disorders, and cancer. They offer clinical support, equipment, and supplies necessary for patients receiving infusion treatments outside of a hospital setting.
- Healthcare Equipment Services: This segment provides services related to infusion pumps and other medical equipment used in the delivery of infusion therapies. This includes rentals, maintenance, and repair services.
Leadership and Structure
The company is led by Richard DiIorio as Chief Executive Officer. The organizational structure includes various departments such as clinical operations, sales and marketing, and finance, all reporting to the executive leadership team.
Top Products and Market Share
Key Offerings
- Infusion Pumps & Related Supplies: InfuSystems provides a range of infusion pumps used for delivering medications and fluids to patients. Their market share is estimated to be in the range of 20-25% of the home infusion market, competing with options from Baxter International (BAX) and Option Care Health (OPCH). Revenue isn't broken out but is assumed to be largest product based on the services offered.
- Clinical Support Services: InfuSystems provides clinical support services, including patient education and monitoring, to ensure effective and safe infusion therapy. This service is typically bundled with pump rentals and supplies, making its revenue difficult to isolate. Key Competitors: Accredo Health Group, CVS Health (CVS)
Market Dynamics
Industry Overview
The infusion therapy market is experiencing growth due to the increasing prevalence of chronic diseases and the shift towards home-based healthcare. Technological advancements in infusion pumps and therapies also contribute to market expansion.
Positioning
InfuSystems is positioned as a provider of comprehensive infusion therapy solutions, focusing on delivering high-quality services and equipment to patients outside of traditional hospital settings. Their competitive advantage lies in their integrated service model and geographic reach.
Total Addressable Market (TAM)
The global infusion therapy market is projected to reach $30 billion by 2027. InfuSystems is positioned to capture a portion of this TAM through its specialized services and focus on the home and ambulatory infusion segments.
Upturn SWOT Analysis
Strengths
- Established presence in the infusion therapy market
- Comprehensive service offerings
- Strong relationships with healthcare providers
- Focus on patient care and safety
Weaknesses
- High reliance on reimbursement rates
- Exposure to regulatory changes
- Competition from larger healthcare providers
- Limited geographic diversification
Opportunities
- Expansion into new geographic markets
- Development of new infusion therapies
- Strategic partnerships with healthcare organizations
- Acquisition of smaller competitors
Threats
- Changes in reimbursement policies
- Increased competition from large healthcare systems
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- OPCH
- CVS
Competitive Landscape
InfuSystems competes with larger healthcare providers and pharmaceutical companies. Their ability to differentiate through specialized services and patient-centric care will be crucial for maintaining a competitive edge.
Major Acquisitions
Haydon Medical
- Year: 2021
- Acquisition Price (USD millions): 20.2
- Strategic Rationale: Haydon Medical expands InfuSystem's infusion distribution services in the United States. It allows the company to reach more patients.
Growth Trajectory and Initiatives
Historical Growth: InfuSystems has demonstrated moderate revenue growth over the past few years, primarily driven by increasing demand for home infusion therapy services.
Future Projections: Analysts project continued revenue growth in the coming years, driven by the aging population and increasing prevalence of chronic diseases. Projected growth rates is expected to be in the low single digits.
Recent Initiatives: Recent initiatives include expanding the network of ambulatory infusion suites and investing in new technologies to improve patient outcomes.
Summary
InfuSystems Holdings Inc. is a key player in the infusion therapy market, offering comprehensive services and equipment. While it has a strong market presence and established relationships, it faces challenges from larger competitors and regulatory changes. Its moderate growth and recent net income decline suggests potential operational inefficiencies. To maintain a competitive edge, InfuSystems should focus on strategic partnerships, market diversification, and cost management.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Analyst Reports
- Industry Publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InfuSystems Holdings Inc
Exchange NYSE MKT | Headquaters Rochester Hills, MI, United States | ||
IPO Launch date 2007-12-27 | President, CEO & Director Ms. Carrie A. Lachance B.S.N., M.B.A., R.N. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 502 | Website https://www.infusystem.com |
Full time employees 502 | Website https://www.infusystem.com | ||
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates in two segments, Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.